RYR1 and glioblastoma: Cyto-C specimen sets thus have substantial value for use in the discovery phase of other potential GBM markers.24 The Cyto-C study has many components of a PRoBE design.25 Indeed, the Cyto-C study is the first in which biological specimens were collected prospectively from a single cohort of patients with newly diagnosed GBM, which represented the population envisioned for clinical application of the potential biomarker (ie, tumor CcO activity and MGMT promoter methylation status).